Get started
VERTEX PHARMAC. DL-,01VERTEX PHARMAC. DL-,01VERTEX PHARMAC. DL-,01

VERTEX PHARMAC. DL-,01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VX1 chart


Full chart

VX1 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪117.34 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.00 EUR
Net income (FY)
‪−517.38 M‬ EUR
Revenue (FY)
‪10.61 B‬ EUR
Shares float
‪255.91 M‬
Beta (1Y)
1.13

Employees


Employees (FY)
‪6.1 K‬
Change (1Y)
+700 +12.96%
Revenue / Employee (1Y)
‪1.74 M‬ EUR
Net income / Employee (1Y)
‪−84.82 K‬ EUR

About Vertex Pharmaceuticals Incorporated


Sector
Health Technology
CEO
Reshma Kewalramani
Headquarters
Boston
Website
vrtx.com
Founded
1989
FIGI
BBG000GNZRT2
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VX1 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where VX1 is featured.

See all sparks 

Frequently Asked Questions


The current price of VX1 is 459.00 EUR — it has increased by 0.65% in the past 24 hours. Watch VERTEX PHARMAC. DL-,01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange VERTEX PHARMAC. DL-,01 stocks are traded under the ticker VX1.
VX1 stock has risen by 3.04% compared to the previous week, the month change is a 9.49% rise, over the last year VERTEX PHARMAC. DL-,01 has showed a 15.23% increase.
We've gathered analysts' opinions on VERTEX PHARMAC. DL-,01 future price: according to them, VX1 price has a max estimate of 590.11 EUR and a min estimate of 316.65 EUR. Watch VX1 chart and read a more detailed VERTEX PHARMAC. DL-,01 stock forecast: see what analysts think of VERTEX PHARMAC. DL-,01 and suggest that you do with its stocks.
VX1 reached its all-time high on Nov 11, 2024 with the price of 487.00 EUR, and its all-time low was 6.55 EUR and was reached on Aug 10, 2004. View more price dynamics on VX1 chart.
See other stocks reaching their highest and lowest prices.
VX1 stock is 1.09% volatile and has beta coefficient of 1.13. Track VERTEX PHARMAC. DL-,01 stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMAC. DL-,01 there?
Today VERTEX PHARMAC. DL-,01 has the market capitalization of ‪117.34 B‬, it has increased by 4.56% over the last week.
Yes, you can track VERTEX PHARMAC. DL-,01 financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMAC. DL-,01 is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
VX1 earnings for the last quarter are 3.84 EUR per share, whereas the estimation was 3.88 EUR resulting in a −0.90% surprise. The estimated earnings for the next quarter are 4.05 EUR per share. See more details about VERTEX PHARMAC. DL-,01 earnings.
VERTEX PHARMAC. DL-,01 revenue for the last quarter amounts to ‪2.81 B‬ EUR, despite the estimated figure of ‪2.69 B‬ EUR. In the next quarter, revenue is expected to reach ‪2.72 B‬ EUR.
VX1 net income for the last quarter is ‪881.94 M‬ EUR, while the quarter before that showed ‪938.92 M‬ EUR of net income which accounts for −6.07% change. Track more VERTEX PHARMAC. DL-,01 financial stats to get the full picture.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 26, 2025, the company has ‪6.10 K‬ employees. See our rating of the largest employees — is VERTEX PHARMAC. DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMAC. DL-,01 EBITDA is ‪23.38 M‬ EUR, and current EBITDA margin is 41.56%. See more stats in VERTEX PHARMAC. DL-,01 financial statements.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMAC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMAC. DL-,01 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMAC. DL-,01 stock shows the buy signal. See more of VERTEX PHARMAC. DL-,01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.